15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal
25 nov. 2019 07h00 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento" or the “Company”), confirmed today that on November 23, 2019, it received an unsolicited,...
15-SORRENTO-Therapeutics-Logo-FINAL.png
 Sorrento CEO to Present at Upcoming Investor Conferences
12 nov. 2019 07h05 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in upcoming investor...
15-SORRENTO-Therapeutics-Logo-FINAL.png
 Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
06 nov. 2019 19h37 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento’s research team will...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Los Angeles Court Rejects Patrick Soon-Shiong’s Attempt to Avoid Sorrento Litigation Allowing Arbitration Case to Move Forward
15 oct. 2019 22h36 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that a Los Angeles Superior Court judge has rejected Patrick Soon-Shiong’s attempt...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering
09 oct. 2019 10h35 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Announces $25 Million Registered Direct Offering
07 oct. 2019 14h35 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...
scilex.png
Scilex Announces New Medicaid Agreements with CA & FL
01 oct. 2019 07h00 HE | Scilex Holding Company
PALO ALTO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is excited to announce that its...
scilex.png
Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak
30 sept. 2019 07h00 HE | Scilex Holding Company
PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
23 sept. 2019 07h00 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Dr. Henry Ji to Participate in Multiple Investment Conferences in September 2019 to Provide Corporate Updates
05 sept. 2019 08h00 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in multiple investment...